These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31713445)

  • 41. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
    Witteles RM; Bokhari S; Damy T; Elliott PM; Falk RH; Fine NM; Gospodinova M; Obici L; Rapezzi C; Garcia-Pavia P
    JACC Heart Fail; 2019 Aug; 7(8):709-716. PubMed ID: 31302046
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR).
    Vita GL; Stancanelli C; Gentile L; Barcellona C; Russo M; Di Bella G; Vita G; Mazzeo A
    Neuromuscul Disord; 2019 Mar; 29(3):213-220. PubMed ID: 30718023
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of Right Ventricular Strain Measured by Two-Dimensional Echocardiography in the Diagnosis of Cardiac Amyloidosis.
    Moñivas Palomero V; Durante-Lopez A; Sanabria MT; Cubero JS; González-Mirelis J; Lopez-Ibor JV; Navarro Rico SM; Krsnik I; Dominguez F; Mingo AM; Hernandez-Perez FJ; Cavero G; Santos SM
    J Am Soc Echocardiogr; 2019 Jul; 32(7):845-853.e1. PubMed ID: 31078369
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [What gnaws at the heart and gets on the nerves].
    Kristen AV
    Internist (Berl); 2018 Nov; 59(11):1208-1213. PubMed ID: 30039176
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
    Adams D; Polydefkis M; González-Duarte A; Wixner J; Kristen AV; Schmidt HH; Berk JL; Losada López IA; Dispenzieri A; Quan D; Conceição IM; Slama MS; Gillmore JD; Kyriakides T; Ajroud-Driss S; Waddington-Cruz M; Mezei MM; Planté-Bordeneuve V; Attarian S; Mauricio E; Brannagan TH; Ueda M; Aldinc E; Wang JJ; White MT; Vest J; Berber E; Sweetser MT; Coelho T;
    Lancet Neurol; 2021 Jan; 20(1):49-59. PubMed ID: 33212063
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
    Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis?
    Suhr OB; Anan I; Backman C; Karlsson A; Lindqvist P; Mörner S; Waldenström A
    J Intern Med; 2008 Mar; 263(3):294-301. PubMed ID: 18069997
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid.
    Garcia-Pavia P; Aus dem Siepen F; Donal E; Lairez O; van der Meer P; Kristen AV; Mercuri MF; Michalon A; Frost RJA; Grimm J; Nitsch RM; Hock C; Kahr PC; Damy T
    N Engl J Med; 2023 Jul; 389(3):239-250. PubMed ID: 37212440
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inotersen and severe thrombocytopenia: 2 case reports and review.
    Domínguez Senín L; Borrachero Garro C; Sánchez Gómez E; Santos-Rubio MD
    Int J Clin Pharmacol Ther; 2022 Jul; 60(7):311-316. PubMed ID: 35343431
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Letter by Baldovino et al Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy".
    Baldovino S; Costanzo P; Roccatello D
    Circ Heart Fail; 2022 Jul; 15(7):e009617. PubMed ID: 35748294
    [No Abstract]   [Full Text] [Related]  

  • 51. Natural History and Disease Progression of Early Cardiac Amyloidosis Evaluated by Echocardiography.
    Itzhaki Ben Zadok O; Eisen A; Shapira Y; Monakier D; Iakobishvili Z; Schwartzenberg S; Abelow A; Ofek H; Kazum S; Ben-Avraham B; Hamdan A; Bental T; Sagie A; Kornowski R; Vaturi M
    Am J Cardiol; 2020 Oct; 133():126-133. PubMed ID: 32811652
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real-life experience with inotersen at CEPARM, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro.
    Dias M; Pinto LF; Pinto MV; Gervais R; Accioli P; Amorim G; Guedes M; Gomes CP; Pedrosa RC; Waddington-Cruz M
    Arq Neuropsiquiatr; 2024 Apr; 82(4):1-7. PubMed ID: 38579737
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.
    Waddington-Cruz M; Ackermann EJ; Polydefkis M; Heitner SB; Dyck PJ; Barroso FA; Wang AK; Berk JL; Dyck PJB; Monia BP; Hughes SG; Tai L; Jesse Kwoh T; Jung SW; Coelho T; Benson MD; Gertz MA
    Amyloid; 2018 Sep; 25(3):180-188. PubMed ID: 30169969
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report.
    Kristen AV; Lehrke S; Buss S; Mereles D; Steen H; Ehlermann P; Hardt S; Giannitsis E; Schreiner R; Haberkorn U; Schnabel PA; Linke RP; Röcken C; Wanker EE; Dengler TJ; Altland K; Katus HA
    Clin Res Cardiol; 2012 Oct; 101(10):805-13. PubMed ID: 22584381
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and efficacy of diflunisal in transthyretin cardiac amyloidosis.
    Peiró-Aventín B; Cabrera-Romero E; Mora-Ayestarán N; Domínguez F; González-López E; García-Pavía P
    Rev Esp Cardiol (Engl Ed); 2024 May; 77(5):426-428. PubMed ID: 38325700
    [No Abstract]   [Full Text] [Related]  

  • 56. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.
    Judge DP; Heitner SB; Falk RH; Maurer MS; Shah SJ; Witteles RM; Grogan M; Selby VN; Jacoby D; Hanna M; Nativi-Nicolau J; Patel J; Rao S; Sinha U; Turtle CW; Fox JC
    J Am Coll Cardiol; 2019 Jul; 74(3):285-295. PubMed ID: 30885685
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diffusion Tensor Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.
    Khalique Z; Ferreira PF; Scott AD; Nielles-Vallespin S; Martinez-Naharro A; Fontana M; Hawkins P; Firmin DN; Pennell DJ
    Circ Cardiovasc Imaging; 2020 May; 13(5):e009901. PubMed ID: 32408830
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Focal Segmental Glomerulosclerosis Complicating Therapy With Inotersen, an Antisense Oligonucleotide Inhibitor: A Case Report.
    Law S; Arnold J; Rauf MU; Heptinstall L; Gilbertson J; Rowczenio D; Baharani J; Langman G; Fontana M; Gillmore JD
    Am J Kidney Dis; 2023 May; 81(5):606-610. PubMed ID: 36228827
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy.
    Coutinho MC; Cortez-Dias N; Cantinho G; Conceição I; Oliveira A; Bordalo e Sá A; Gonçalves S; Almeida AG; de Carvalho M; Diogo AN
    Circ Cardiovasc Imaging; 2013 Sep; 6(5):627-36. PubMed ID: 23833285
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Extracellular Volume Detects Amyloidotic Cardiomyopathy and Correlates With Neurological Impairment in Transthyretin-familial Amyloidosis.
    Gallego-Delgado M; González-López E; Muñoz-Beamud F; Buades J; Galán L; Muñoz-Blanco JL; Sánchez-González J; Ibáñez B; Mirelis JG; García-Pavía P
    Rev Esp Cardiol (Engl Ed); 2016 Oct; 69(10):923-930. PubMed ID: 27291669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.